Keywords: proacta, raises, 35m, fund, its, pr-104, development

Proacta raises $35M to fund its PR-104 development

Article | 19 February 2007

Print This

Proacta, a clinical stage biotechnology company first founded in New Zealand, has completed a $35.0 million series B financing. The new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in